Envoy Medical, Inc. (COCHW) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-11

Key Insights

Envoy Medical filed an 8-K solely to disclose Q1 2026 earnings results via press release, indicating a routine quarterly earnings announcement with no material corporate events or strategic developments.
The company maintains its emerging growth company status, which provides regulatory flexibility but suggests the firm is still in earlier stages of public company maturity.
The filing contains minimal substantive information beyond referencing an attached press release, making it impossible to assess actual financial performance, revenue trends, or margin changes from the 8-K alone.

Want the newest filings?

This analysis covers the filing from 2026-05-11. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-31

Envoy Medical, Inc. has dismissed its previous independent auditor, Grant Thornton LLP, and appointed a new one, EisnerAmper LLP, for the fiscal year ending December 31, 2026.
The dismissal of Grant Thornton was due to a competitive process, and there were no reported disagreements or reportable events, except for previously disclosed material weaknesses in internal control over financial reporting.
The appointment of EisnerAmper as the new independent auditor suggests Envoy Medical is taking steps to address the identified internal control issues and improve the quality of its financial reporting.

Filed: 2026-03-27

Envoy Medical, Inc. issued a press release on March 23, 2026, reporting its financial results for the fourth fiscal quarter and fiscal year ended December 31, 2025.
The company's Class A Common Stock and Redeemable Warrants are traded on the Nasdaq Stock Market under the ticker symbols 'COCH' and 'COCHW' respectively.
Envoy Medical is classified as an emerging growth company, indicating it may have fewer reporting requirements compared to more established public companies.

Filed: 2026-02-27

Envoy Medical, Inc. has regained compliance with the Nasdaq Listing Rule 5550(b)(2), allowing it to maintain its listing on the Nasdaq exchange.
The company will be subject to a one-year discretionary panel monitor by Nasdaq, indicating additional scrutiny and oversight from the exchange.
The press release announcing the Nasdaq compliance confirmation suggests a positive development for the company, though the specific details of the prior non-compliance are not provided.

Filed: 2026-02-13

Envoy Medical is conducting a best efforts public offering of common stock, pre-funded warrants, and two series of common warrants, raising significant capital to support its operations.
Certain company insiders, including directors, officers, and a major shareholder, participated in the offering, purchasing a substantial portion of the shares and warrants at the same price as other investors.
The company has agreed to seek shareholder approval for the issuance of shares upon exercise of the common warrants within 90 days, and to continue calling meetings every 90 days until approval is obtained.

Filed: 2026-02-11

Envoy Medical, Inc. granted stock options to its Chief Executive Officer and Interim Chief Financial Officer under the company's 2023 Equity Incentive Plan, aligning their interests with shareholders.
The options have an exercise price of $0.53 per share, with 25% vesting after one year and the remainder vesting pro rata over the following 36 months, incentivizing long-term value creation.
As an emerging growth company, Envoy Medical may benefit from the extended transition period for complying with new or revised financial accounting standards, providing flexibility to focus on growth initiatives.

Filed: 2025-12-29

Envoy Medical extended the expiration date of 1,125,499 outstanding Shortfall Warrants from December 31, 2025 to December 31, 2026, providing warrant holders additional time to exercise.
The exercise price of the Shortfall Warrants is determined based on a volume weighted average price (VWAP) formula, subject to a minimum price of $1.50 per share, potentially limiting the upside for warrant holders.
The issuance and resale of the shares underlying the Shortfall Warrants have been registered, providing liquidity for the warrant holders.

Other reports for Envoy Medical, Inc.

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.